Growth inhibition of non-small cell lung cancer cells by AP-1 blockade using a cJun dominant-negative mutant

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• cJun, a key component of the Activator Protein-1 (AP-1) transcription factor, is often overexpressed in non-small cell lung cancers (NSCLCs).
• AP-1 plays a role in transducing mitogenic growth signals, contributing to cancer development.

Purpose of the Study:

• To investigate the impact of blocking AP-1 activity on NSCLC cell proliferation.
• To evaluate the therapeutic potential of a cJun dominant-negative mutant, TAM67, in NSCLC models.

Main Methods:

• Utilized a cJun dominant-negative mutant (TAM67) to inhibit AP-1 transcriptional activity in NSCLC cell lines (NCI-H1299, A549, NCI-H520).
• Established doxycycline-inducible TAM67-expressing H1299 clone cells for controlled studies.
• Assessed anchorage-dependent and -independent growth, cell-cycle progression (G1 block), apoptosis, cyclin A expression, and xenograft tumor growth in nude mice.

Main Results:

• Transiently transfected TAM67 inhibited AP-1 activity in H1299, A549, and H520 cells.
• TAM67 reduced colony-forming efficiency in H1299 and A549 cells.
• Induced TAM67 in H1299 cells promoted G1 cell-cycle arrest, decreased cyclin A expression, and inhibited both anchorage-dependent and -independent growth.
• TAM67 significantly reduced the growth of established NSCLC xenograft tumors in vivo.

Conclusions:

• AP-1 blockade using TAM67 effectively inhibits NSCLC cell growth through cell-cycle arrest.
• These findings highlight the essential role of AP-1 in the proliferation of certain NSCLC types.
• Targeting AP-1 represents a potential therapeutic strategy for NSCLC.